FUSN — Fusion Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.83bn
- $1.67bn
- $2.07m
Annual cashflow statement for Fusion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.2 | -78.3 | -81 | -87.6 | -94.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.817 | 42.9 | 20.3 | 12.9 | 12.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.08 | 5.74 | -14.6 | 3.66 | -1.32 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -13.7 | -29.8 | -75.7 | -73.3 | -81.8 |
| Capital Expenditures | -0.456 | -1.12 | -1.49 | -2.14 | -3.89 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -209 | 39.3 | 25.2 | -38.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.456 | -210 | 37.8 | 23.1 | -42.8 |
| Financing Cash Flow Items | — | -4.57 | -0.275 | 0 | -4.03 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 52.2 | 266 | 0.347 | 40.7 | 142 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 38 | 25.3 | -37.6 | -9.46 | 17.4 |